Treatment of fragile X syndrome with cannabidiol
US12226373B2 · kind B2 · utility
0Cited by
21References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 2023 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Aug 30, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.